Markush Claims

What are Markush claims?

A Markush claim is a claim format — most common in chemical, pharmaceutical, and biological patents — that covers a group of related alternatives within a single claim using the language 'selected from the group consisting of.' Rather than filing separate claims for each compound in a related chemical family, a Markush claim covers the entire class at once. The format is named after Eugene Markush, a chemist whose 1924 application for certain pyrazolone dyes used this structure and was approved by the USPTO after an appeal. The Markush format allows patent protection for a genus of compounds when the inventor has discovered a class of related molecules that share a useful property.

The 'selected from the group consisting of' language

The defining phrase in Markush claims is 'selected from the group consisting of,' which creates a closed group — only members explicitly listed can satisfy the claim element. The phrase 'consisting of' is a closed transitional phrase in patent drafting, meaning no additional members outside those listed can be substituted. A simple example: 'a compound having formula X wherein R is selected from the group consisting of methyl, ethyl, propyl, and isopropyl.' This single claim covers four compounds. More complex pharmaceutical patents may use nested Markush structures — groups within groups — to cover entire chemical families while maintaining claim validity under § 112.

Why Markush claims matter in pharmaceutical patents

In pharmaceutical patent practice, Markush claims are essential. Drug discovery typically proceeds by identifying a lead compound and then synthesizing and testing hundreds of structural analogs to find the best candidate in terms of efficacy, selectivity, pharmacokinetics, and safety. A pharmaceutical patent covering only the single best candidate would leave competitors free to make and sell closely related analogs that perform similarly. Markush claims covering the broader chemical class protect the inventor's investment in discovering the pharmacophore (the molecular feature responsible for the biological activity), not just the single best molecule. Many major drug patents cover broad Markush genus claims that may include thousands of theoretically possible but never-actually-synthesized compounds.

Proper vs. improper Markush groups

The USPTO requires that the members of a Markush group be a 'proper' group — meaning either (1) all members belong to a recognized class of materials (like alkyl groups, halogens, or amino acids) or (2) all members share a common structural feature and a common property or activity. If the grouped members are unrelated and cannot reasonably be expected to be interchangeable for the claimed purpose, the examiner will require separate claiming. For instance, 'selected from the group consisting of methyl, hydrogen, and hydroxyl' is problematic if these substituents have materially different effects on the claimed property. The requirement for a proper Markush group prevents claim drafters from aggregating unrelated alternatives to avoid paying multiple claims fees.

Nested Markush structures

Advanced pharmaceutical patent claims often use nested Markush structures — Markush groups within Markush groups. For example: 'a compound of formula I, wherein: R1 is selected from the group consisting of hydrogen and C1-C4 alkyl; R2 is selected from the group consisting of phenyl, halophenyl, and methylphenyl; and R3 is selected from the group consisting of hydrogen, methyl, and ethyl.' With three independently variable positions, this claim covers 2 × 3 × 3 = 18 possible compounds. More complex structures with many variable positions can cover millions of theoretically possible compounds. Such broad claims invite § 112 written description and enablement challenges if the patent specification does not demonstrate possession and operability across the full scope.

Written description and enablement for Markush genera

Broad Markush genus claims face heightened scrutiny under 35 U.S.C. § 112(a) for written description and enablement. The Federal Circuit has held that to satisfy the written description requirement for a genus claim, the specification must demonstrate that the inventor had possession of the full claimed genus — not just representative examples. In AbbVie Deutschland v. Janssen Biotech (2014), the court invalidated antibody claims for inadequate written description because the disclosed examples did not adequately represent the full claimed genus of antibodies. For small-molecule Markush claims, disclosure of representative examples from each structural subcategory in the genus is important. For very large genera, the specification should explain the common structural or functional feature that unifies the group.

Unity of invention and restriction requirements

Markush claims with very large groups of alternatives may also face restriction requirements at the USPTO under the unity of invention doctrine. If the alternatives in a Markush claim are so diverse that they belong to different inventive concepts — i.e., they are not obvious variants of each other and do not share a technical relationship — the examiner may require the applicant to elect one subset of alternatives for prosecution and file divisional applications for the others. At the EPO, Markush claims are subject to the unity of invention requirement under EPC Rule 44 and European Patent Office Guidelines, which require all claimed subject matter to be linked by a single general inventive concept.

Infringement by a Markush claim

A product infringes a Markush claim if it literally falls within one of the listed group members and satisfies all other elements of the claim. For example, if a patent claims 'a compound selected from the group consisting of compound A, compound B, and compound C,' a competitor who makes compound A infringes regardless of which member they chose — as long as that member is in the list, infringement is established for that member. Doctrine of equivalents analysis can also apply to Markush claims, potentially covering compounds not literally in the listed group but substantially equivalent to listed members — though prosecution history estoppel may limit this for alternatives deliberately excluded from the group during prosecution.

Frequently Asked Questions